Journal of Clinical Pathways
January 31, 2025
The impact of Fluoropyrimidines-induced severe toxicity can no longer be overlooked. Preemptive genetic testing for DPYD pathogenic variants must become standard practice to identify at-risk patients and prevent life-threatening complications, positioning DPYD testing as a public health priority. - Houda Hachad, VP of Clinical Operations at Aranscia
Click here to watch "Recommendations for Standardizing DPYD Pharmacogenomic Testing" - an interview between Houda Hachad and the Journal of Clinical Pathways.